-
Successful treatment of Weber-Christian disease with Cyclosporin-A. Am J Med. 1988; 85: 276-278.
Usuki K, Kitamura K, Urabe A, Takaku F.
-
Herpes zoster, postherpetic neuralgia, and Interferon-gamma. Ann Intern Med. 1988; 108: 643-644.
Usuki K, Kitamura K, Urabe A, Takaku F.
-
Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature. 1989; 338(6216); 557-562.
Ishikawa F, Miyazono K, Hellman U, Dreter H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W, Heldin C-H.
-
Production of platelet-derived endothelial cell growth factor by normal and transformed human cells in culture. Proc Natl Acad Sci USA. 1989; 86; 7427-7431.
Usuki K, Heldin N-E, Miyazono K, Ishikawa F, Takaku F, Westermark B, Heldin C-H.
-
Localization of platelet-derived endothelial cell growth factor in human placenta and purification of an alternatively processed form. Cell Regul. 1990: 1; 577-596.
Usuki K, Norberg L, Larsson E, Miyazono K, Hellman U, Wernstedt C, Rubin K, Heldin C-H.
-
Covalent linkage between nucleotides and platelet-derived endothelial cell growth factor. J Biol Chem. 1991; 266; 20525-20531.
Usuki K, Miyazono K, Heldin C-H.
-
Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochem Biophys Res Commun. 1992; 184 (3); 1311-1316.
Usuki K, Saras J, Waltenberger J, Miyazono K, Pierce G, Thomason A, Heldin C-H.
-
Structural properties of 3.0 kb and 3.2 kb transcripts encoding platelet-derived endothelial cell growth factor/thymidine phosphorylase in A431 cells. Biochim Biophys Acta. 1994; 1222 (3); 411-414.
Usuki K, Gonez LJ, Wernstedt C, Morén A, Miyazono K, Claesson-Welsh L, Heldin CH.
-
Filgrastim combined with tretinoin in acute promyelocytic leukemia. Lancet. 1994; 343; 803-804.
Usuki K, Ikeda Y, Kitazume K, Iwabe K, Okuyama Y, Urabe A.
-
Granulocyte-colony stimulating factor in acute myeloid leukemia. Stem CellSs. 1995; 13; 647-654.
Usuki K, Iki S, Endo M, Kitazume K, Ito K, Watanabe M, Urabe A.
-
Administration of granulocyte colony-stimulating factor during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Int J Hematol, 1996; 64; 213-219.
Usuki K, Nishizawa Y, Endo M, Osawa M, Kitazume K, Iki S, Watanabe M, Urabe A.
-
Serum thrombopoietin level in various hematological diseases. Stem cells, 1996; 14; 558-565.
Usuki K, Tahara T, Iki S, Endo M, Osawa M, Kitazume K, Kato T, Miyazaki H, Urabe A.
-
Dfferentiation effect of acyclic retinoid on acute promyelocytic luekemia (APL) cells. Ann Hematol. 1996; 73; 219-224.
Usuki K, Urabe A, Tojo A, Moriwaki H, Tsurumi H, Ikeda Y, Kizaki M, Toyama K, Aizawa M, Inai K, Muto Y, Asano S, Takaku F.
-
Influences of thrombopoietin on the platelet activation in myeloproliferative disorders. Br J Haematol. 1997; 97; 530-537.
Usuki K, Iki S, Endo M, Izutsu K, Inoue K, Nishimura T, Urabe A.
-
Serum Leptin Levels during Cancer Chemotherapy. Ann Hematol. 1998; 77; 191-192.
Usuki K, Okazaki R, Iki S, Muramatsu M, Yamaguchi Y, Totsuka Y, Urabe A.
-
Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukemia: a multicentre randomized study. Br J Haematol. 2002; 116; 103-112.
Usuki K, Urabe A, Masaoka T, Ohno R, Mizoguchi H, Hamajima N, Miyazaki T, Niitsu Y, Yoshida Y, Miura A, Shibata A, Abe T, Miura Y, Ikeda Y, Nomura T, Nagao T, Saitou H, Shirakawa S, Ohkuma M, Matsuda T, Nakamura T, Horiuchi A, Kuramoto A, Kimura I, Irino S, Niho Y, Takatsuki K, Tomonaga M, Uchino H, Takaku F; Gran AML Study Group.
-
CML Cytogenetic Relapse After Cessation of Imatinib Therapy. Leukemia Res. 2005; 29(2) ; 237-8.
Usuki K, Iijima K, Iki S, Urabe A.
-
Stable Response after Administration of Stem Cell Factor Combined with Granulocyte Colony-Stimulating Factor in Aplastic Anemia. Int J Hematol, 2006; 83(6); 404-7.
Usuki K, Iki S, Arai S, Iijima K, Takaku F, Urabe A.
-
Lower leukocytes at initial diagnosis may predict poor outcome of very late relapse of acute lymphoblastic leukemia. Leukmia Res. 2008; 32; 659-664.
Nakasone H, Kida M, Iki S, Usuki K.
-
Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia. Biol Blood Marrow Transplant. 2008; 14(11); 1262-1269.
Nakasone H, Izutsu K, Wakita S, Yamaguchi H, Muramatsu-Kida M, Usuki K.
-
CD8+ memory T cells predominate over naïve T cells in therapy-free CML patients with sustained major molecular response. Leukemia Res. 2009; 33: e164-e165.
Usuki K, Yokoyama K, Nagamura-Inoue T, Ito A, Kida M, Izutsu K, Urabe A, Tojo A.
-
Pancreatic atrophy is associated with gastrointestinal chronic GVHD following allogeneic PBSC transplantation. Bone Marrow Transplant. 2010; 45; 590–592.
Nakasone H, Ito A, Endo H, Kida M, Koji I, Usuki K.
-
Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study. Int J Hematol. 2012; 95:409–419.
Usuki K, Tojo A, Maeda Y, Kobayashi Y, Matsuda A, Ohyashiki K, Nakaseko C, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Okamoto S, Oritani K, Okada M, Usui N, Nagai T, Amagasaki T, Wanajo A, Naoe T.
-
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012; 97(6): 903-906.
Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, Usui N, Okamoto S, Ohe Y, Ohtake S, Kitamura K, Yamamoto M, Teshima H, Motoji T, Tamaki T, Sawada K, Ohyashiki K.
-
Comparison of Autologous Hematopoietic Cell Transplantation and Chemotherapy as Postremission Treatment in Non-M3 Acute Myeloid Leukemia in First Complete Remission. Clin Lymphoma Myeloma Leuk. 2012; 12 (6): 444-51.
Usuki K, Kurosawa S, Uchida N, Yakushiji K, Waki F, Matsuishi E, Kagawa K, Furukawa T, Maeda Y, Shimoyama M, Ago H, Yamano Y, Yano S, Fujishima N, Takamatsu Y, Eto T, Hidaka M, Matsuoka H, Fukuda T.
-
Recurrent CDC25C mutations drive malignant transformation in FPD/AML. Nature Commun. 2014; 5: 4770.
Yoshimi A, Toya T, Kawazu M, Ueno T, Tsukamoto A, Iizuka H, Nakagawa M, Nannya Y, Arai S, Harada H, Usuki K, Hayashi Y, Ito E, Kirito K, Nakajima H, Ichikawa M, Mano H, Kurokawa M.
-
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015; 2(12): e528-35.
Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Morita S, Sakamoto J, Kimura S; DADI Trial Group.
-
Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study. Cancer Sci. 2018; 109(10): 3235-3244.
Usuki K, Sakura T, Kobayashi Y, Miyamoto T, Iida H, Morita S, Bahceci E, Kaneko M, Kusano M, Yamada S, Takeshita S, Miyawaki S, Naoe T.
-
Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study. Int J Hematol. 2019; 110(6): 654-664.
Usuki K, Handa H, Choi I, Yamauchi T, Iida H, Hata T, Ohwada S, Okudaira N, Nakamura K, Sakajiri S.
-
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020; 135(12): 912-920.
Röth A, Nishimura JI, Nagy Z, Gaàl-Weisinger J, Panse J, Yoon SS, Egyed M, Ichikawa 7, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R.
-
【共著】臼杵憲祐、PD-ECGF, 分子血液学, 高久史麿編、南江堂, pp.187-194, 1991.
-
【共著】臼杵憲祐、癌と細胞増殖因子, 細胞増殖因子の最前線ー臨床医のための実験医学シリーズ10、門脇孝編集、羊土社、pp119-128, 1993.
-
【共著】臼杵憲祐、本態性血小板血症、日本内科学会雑誌、96(7); 1390-1397, 2007
-
【共著】臼杵憲祐 .血球貪食症候群、今日の治療指針2010年版、編集:山口徹、北原光夫、福井次矢、医学書院 p560-561, 2010.
-
【共著】中尾眞二、檀和夫、小島勢二、大橋春彦、小原明、泉二登志子、臼杵憲祐、浦部晶夫、松田晃、唐沢正光、大屋敷一馬、石川隆之、澤田賢一、寺村正尚、再生不良性貧血、難治性貧血の診療ガイド 特発性造血障害の病態・診断・治療の最新動向、「難治性貧血の診療ガイド」編集委員会編 南江堂、東京, p.11-30, 2011.
-
【共著】臼杵憲祐. 再生不良性貧血、今日の治療指針2012年版、編集:山口徹、北原光夫、福井次矢、医学書院 p567-569, 2012.
-
【共著】臼杵憲祐、異食症、In: 別冊日本臨床 新領域別症候群シリーズ「血液症候群 第2版—その他の血液疾患を含めてー I巻」、日本臨床、東京、2013、pp130-133
-
【共著】臼杵憲祐、Plummer-Vinson症候群、In: 別冊日本臨床 新領域別症候群シリーズ「血液症候群 第2版—その他の血液疾患を含めてー I巻」、日本臨床、東京、2013、pp127-129
-
【共著】臼杵憲祐、骨髄不全(再生不良性貧血、骨髄異形成症候群)、in G−CSFの基礎と臨床、東條有伸編、医薬ジャーナル社、大阪、p138-153, 2013.
-
【共著】臼杵憲祐、急性リンパ性白血病の治療、日本内科学会雑誌 2013, 102; 1696-1704.
-
【共著】臼杵憲祐、冷式抗体による自己免疫性溶血性貧血、内科 2013, 112(2); 271-274.
-
【共著】臼杵憲祐、溶血性貧血:診断と治療、特集 貧血:基礎知識から治療の最前線まで、日本内科学会雑誌、104(7); 1389-1396, 2015
-
【共著】臼杵憲祐、発作性夜間ヘモグロビン尿症の妊娠・分娩管理、臨床血液、56(7); 785-794, 2015
-
【共著】臼杵憲祐、遺伝子球状赤血球症、in 今日の診断指針、第7版、総編集 金沢一郎、長い良三、医学書院、p.1131-1133、2015
-
【共著】臼杵憲祐、寒冷凝集素症、貧血学 最新の診断・治療動向 日本臨床 75(増刊号1); 484-492, 2017
-
【共著】臼杵憲祐、発作性寒冷ヘモグロビン尿症、貧血学 最新の診断・治療動向 日本臨床 75(増刊号1); 493-4998, 2017
-
【共著】臼杵憲祐、急性骨髄性白血病、in 今日の治療指針、2018年版、医学書院、p656-659、2018
-
【共著】臼杵憲祐、再生不良性貧血(汎血球減少症)、医薬品副作用学(第 3 版)下 ―薬剤の安全使用アップデート― VI.臓器・系統別副作用各論―重大な副作用を中心に― 再生不良性貧血(汎血球減少症) 日本臨牀 77(増刊号4): 159-162, 2019
-
【共著】臼杵憲祐、巨赤芽球性貧血、血液・造血器疾患、内科学書 vol6、改訂第9版、中山書店115-119, 2019